JP2012522246A - フィブリンの及びフィブリノーゲンの分解産物の検出、及びこれに関連する産生方法、並びに癌の検出及び監視のための使用方法 - Google Patents

フィブリンの及びフィブリノーゲンの分解産物の検出、及びこれに関連する産生方法、並びに癌の検出及び監視のための使用方法 Download PDF

Info

Publication number
JP2012522246A
JP2012522246A JP2012503382A JP2012503382A JP2012522246A JP 2012522246 A JP2012522246 A JP 2012522246A JP 2012503382 A JP2012503382 A JP 2012503382A JP 2012503382 A JP2012503382 A JP 2012503382A JP 2012522246 A JP2012522246 A JP 2012522246A
Authority
JP
Japan
Prior art keywords
fdp
antibody
cancer
fragment
fibrin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012503382A
Other languages
English (en)
Japanese (ja)
Inventor
スモール−ハワード、アンドレア
Original Assignee
エイエムディーエル インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エイエムディーエル インコーポレイテッド filed Critical エイエムディーエル インコーポレイテッド
Publication of JP2012522246A publication Critical patent/JP2012522246A/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/536—Immunoassay; Biospecific binding assay; Materials therefor with immune complex formed in liquid phase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745—Assays involving non-enzymic blood coagulation factors
    • G01N2333/75—Fibrin; Fibrinogen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
JP2012503382A 2009-03-30 2009-03-30 フィブリンの及びフィブリノーゲンの分解産物の検出、及びこれに関連する産生方法、並びに癌の検出及び監視のための使用方法 Pending JP2012522246A (ja)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2009/038833 WO2010114514A1 (en) 2009-03-30 2009-03-30 Detection of fibrin and fibrinogen degradation products and associated methods of production and use for the detection and monitoring of cancer

Publications (1)

Publication Number Publication Date
JP2012522246A true JP2012522246A (ja) 2012-09-20

Family

ID=41278698

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012503382A Pending JP2012522246A (ja) 2009-03-30 2009-03-30 フィブリンの及びフィブリノーゲンの分解産物の検出、及びこれに関連する産生方法、並びに癌の検出及び監視のための使用方法

Country Status (9)

Country Link
EP (1) EP2414843A1 (zh)
JP (1) JP2012522246A (zh)
KR (1) KR20120057562A (zh)
CN (1) CN102405413A (zh)
AU (1) AU2009343805A1 (zh)
BR (1) BRPI0924286A2 (zh)
CA (1) CA2755486A1 (zh)
RU (1) RU2011143747A (zh)
WO (1) WO2010114514A1 (zh)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2014513949A (ja) * 2011-04-20 2014-06-19 トラクソン・リミテッド・ライアビリティ・カンパニー 患者における癌の診断方法
CA2847839A1 (en) 2011-09-07 2013-03-14 Genway Biotech, Inc. Diagnostic assay to predict cardiovascular risk
WO2015006713A1 (en) 2013-07-12 2015-01-15 Emory University Diagnostic assay to predict cardiovascular risk
CN103954758A (zh) * 2014-05-15 2014-07-30 海南世济医学技术有限公司 一种用于纤维蛋白和纤维蛋白原及其降解产物的检测方法和试剂盒
CN104062436B (zh) * 2014-06-06 2016-02-10 上海良润生物医药科技有限公司 Fxyd在制备诊断和预示肺癌标志物中的应用及fxyd双抗夹心elisa检测试剂盒
GB201518466D0 (en) * 2015-10-19 2015-12-02 Cizzle Biotechnology Ltd Use
RU2742279C2 (ru) * 2016-02-22 2021-02-04 ЭлЭсАй МЕДИЕНС КОРПОРЕЙШН Реагент для оценки продукта расщепления перекрестносшитого фибрина и способ такой оценки
JP6667380B2 (ja) * 2016-06-17 2020-03-18 シスメックス株式会社 血液分析のための方法、血液分析装置、コンピュータプログラム、キャリブレータセット、及びキャリブレータセットの作製方法
CN106680482A (zh) * 2016-12-23 2017-05-17 上海良润生物医药科技有限公司 尿液fxyd检测试剂盒
TW202313954A (zh) * 2021-09-28 2023-04-01 華宇藥品股份有限公司 同伴動物的生物標記偵測方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040033544A1 (en) * 2000-03-07 2004-02-19 Ngo That T. Polyclonal antibodies against fibrinogen degradation products and associated methods of production and use

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU7713498A (en) * 1997-06-03 1998-12-21 Amdl, Inc. Immunoassay for the detection of cancer

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040033544A1 (en) * 2000-03-07 2004-02-19 Ngo That T. Polyclonal antibodies against fibrinogen degradation products and associated methods of production and use

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6013002955; Ｍａｓａｏ　Ｔａｎａｋａ　ａｎｄ　Ｔａｋｅｓｈｉ　Ｏｈｋｉｔａ: 'Ａｎａｌｙｓｉｓ　ｏｆ　Ｆｉｂｒｉｎｏｇｅｎ　Ｄｅｇｒａｄａｔｉｏｎ　Ｐｒｏｄｕｃｔ　ｉｎ　Ｓｅｖｅｒｅ　Ｌｉｖｅｒ　Ｄｉｓｏｒｄｅｒｓ　ｂｙ　Ｉｍｍｕｎｏｂｌｏｔｔｉｎｇ' Ｔｈｅ　Ｔｏｈｏｋｕ　Ｊｏｕｒｎａｌ　ｏｆ　Ｅｘｐｅｒｉｍｅｎｔａｌ　Ｍｅｄｉｃｉｎｅ Ｖｏｌ．　１５３　ｐｐ．　１７９-１８７, 1987 *

Also Published As

Publication number Publication date
CA2755486A1 (en) 2010-10-07
WO2010114514A1 (en) 2010-10-07
RU2011143747A (ru) 2013-05-10
CN102405413A (zh) 2012-04-04
EP2414843A1 (en) 2012-02-08
BRPI0924286A2 (pt) 2016-01-26
AU2009343805A1 (en) 2011-09-29
KR20120057562A (ko) 2012-06-05

Similar Documents

Publication Publication Date Title
JP2012522246A (ja) フィブリンの及びフィブリノーゲンの分解産物の検出、及びこれに関連する産生方法、並びに癌の検出及び監視のための使用方法
US8580520B2 (en) YKL-40 as a marker for gastrointestinal cancers
JP6075881B2 (ja) 乳癌のバイオマーカー
US11506674B2 (en) Monoclonal antibody against D-dimer and diagnosis agent for detecting D-dimer, crosslinked fibrin and its derivatives containing D-dimer by using the antibody
US20110251097A1 (en) Diagnostic kit of colon cancer using colon cancer related marker and diagnostic method thereof
CN113287013A (zh) 溃疡性大肠炎以及原发性硬化性胆管炎的检查方法
EP2982987A1 (en) Lateral flow immunoassays for the detection of antibodies against biological drugs
CN107255711B (zh) 骨桥蛋白用于制备或筛选慢加急性肝衰竭诊断试剂的用途
US20100248269A1 (en) Detection of fibrin and fibrinogen degradation products and associated methods of production and use for the detection and monitoring of cancer
AU2010249401B2 (en) Akt phosphorylation at Ser473 as an indicator for taxane-based chemotherapy
US20120107295A1 (en) Methods and Compositions for Detecting Pancreatic Disease
KR101495225B1 (ko) Ast 양의 측정을 통한 간 질환 진단, 예후 또는 모니터링 키트 및 방법
Plumer et al. Development of fragment-specific osteopontin antibodies and ELISA for quantification in human metastatic breast cancer
JP6975424B2 (ja) 活性構造のＲＥＩＣ／Ｄｋｋ−３タンパク質を特異的に認識して結合する抗体、及び該抗ＲＥＩＣ／Ｄｋｋ−３抗体を用いた癌治療のモニタリング
JP2012502284A (ja) 疾患の処置及び監視の選択用マーカーとしてのｙｋｌ−４０
KR20100127210A (ko) 비특이적 질환용 일반 마커로서의 ｙｋｌ-40
JPH0580053A (ja) ヒト子宮体癌細胞の免疫化学的検出方法
WO2020071457A1 (en) Biomarkers for a combination therapy comprising lenvatinib and everolimus
KR20210006650A (ko) 암의 진단용 조성물
JP7565046B2 (ja) がんの骨転移を検出する方法及び検出試薬
JP7341774B2 (ja) 骨質の評価方法
Brunner et al. RCAS-1 serum and tumor levels in head and neck squamous cell carcinoma
CN117642630A (zh) 用于非酒精性脂肪肝病的纤维化生物标志物
CN110546510A (zh) 预后方法和在所述方法中有用的试剂盒
Henanger Development of an immunoassay for human epidermal growth factor receptor 2 (HER2)

Legal Events

Date Code Title Description
A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20130117

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20130129

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130430

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130509

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20130529

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20130605

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20130903